D
Denise Bradley
Researcher at Hoffmann-La Roche
Publications - 6
Citations - 214
Denise Bradley is an academic researcher from Hoffmann-La Roche. The author has contributed to research in topics: Epirubicin & Pertuzumab. The author has an hindex of 4, co-authored 6 publications receiving 104 citations.
Papers
More filters
Journal ArticleDOI
Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study.
Sandra M. Swain,Michael S. Ewer,Giuseppe Viale,Suzette Delaloge,J-M Ferrero,Mark Verrill,Ramon Colomer,Cláudia Vieira,Theresa L. Werner,Hannah Douthwaite,Denise Bradley,M Waldron-Lynch,Astrid Kiermaier,Jennifer Eng-Wong,Chau T. Dang +14 more
TL;DR: Treatment with pertuzumab, trastuzumAB, and common anthracycline-containing regimens for the neoadjuvant treatment of early breast cancer resulted in cardiac and general safety profiles, and pCR rates, consistent with prior studies with pertizumab.
Proceedings ArticleDOI
Abstract GS3-04: Double-blind placebo (PBO)-controlled randomized phase III trial evaluating first-line ipatasertib (IPAT) combined with paclitaxel (PAC) for PIK3CA/AKT1/PTEN-altered locally advanced unresectable or metastatic triple-negative breast cancer (aTNBC): primary results from IPATunity130 Cohort A
Rebecca Dent,Sung-Bae Kim,Mafalda Oliveira,Carlos Barrios,Joyce O'Shaughnessy,Steven J. Isakoff,Shigehira Saji,Ruffo Freitas-Junior,Manuel Philco,Igor Bondarenko,Qinshu Lian,Denise Bradley,Heather Hinton,Matthew Wongchenko,Aruna Mani,Nicholas C. Turner +15 more
TL;DR: Kim et al. as mentioned in this paper showed that adding IPAT to PAC improved progression-free survival (PFS) with a more pronounced effect in patients with PIK3CA/AKT1/PTEN-altered tumors.
Journal ArticleDOI
Final results of the double-blind placebo-controlled randomized phase 2 LOTUS trial of first-line ipatasertib plus paclitaxel for inoperable locally advanced/metastatic triple-negative breast cancer.
Rebecca Dent,Mafalda Oliveira,Steven J. Isakoff,Seock-Ah Im,Marc Espié,Sibel Blau,Antoinette R. Tan,Cristina Saura,Matthew Wongchenko,Na Xu,Denise Bradley,Sarah-Jayne Reilly,Aruna Mani,Sung Bae Kim,Lotus investigators +14 more
TL;DR: In this article, the authors reported that adding the oral AKT inhibitor ipatasertib to first-line paclitaxel for locally advanced/metastatic triple-negative breast cancer (aTNBC) improved progression-free survival (PFS; primary endpoint), with an enhanced effect in patients with PIK3CA/AKT1/PTEN-altered tumors.
Journal ArticleDOI
IPATunity130: A pivotal randomized phase III trial evaluating ipatasertib (IPAT) + paclitaxel (PAC) for PIK3CA/AKT1/PTEN-altered advanced triple-negative (TN) or hormone receptor-positive HER2-negative (HR+/HER2–) breast cancer (BC).
Rebecca Dent,Sung-Bae Kim,Mafalda Oliveira,Steven J. Isakoff,Carlos H. Barrios,Joyce O'Shaughnessy,Xuyang Lu,Matthew Wongchenko,Denise Bradley,Aruna Mani,José Baselga,Nicholas C. Turner +11 more
TL;DR: The pivotal double-blind placebo (PBO)-controlled randomized phase III IPATunity130 trial (NCT03337724) aims to confirm and build on findings from LOTUS.
Journal ArticleDOI
139O Final results of the double-blind placebo (PBO)-controlled randomised phase II LOTUS trial of first-line ipatasertib (IPAT) + paclitaxel (PAC) for inoperable locally advanced/metastatic triple-negative breast cancer (mTNBC)
Rebecca Dent,Mafalda Oliveira,SJ Isakoff,S-A. Im,Marc Espié,S. Blau,Antoinette R. Tan,Cristina Saura,Matthew Wongchenko,N. Xu,Denise Bradley,S-J. Reilly,Aruna Mani,S-B Kim +13 more